



CONGRESSIONAL CAUCUS ON
**PARKINSON'S
DISEASE**

Join the Congressional Caucus on Parkinson's Disease

The Congressional Caucus on Parkinson's Disease increases lawmakers' awareness of issues impacting the Parkinson's community, including the latest developments in health care-related legislation and medical research. The Caucus supports federal research funding, champions Parkinson's policy priorities, introduces Parkinson's-specific legislation and hosts educational briefings.

Two Senators and three Representatives lead the Caucus: Senators **Debbie Stabenow** (D-MI) and **John Thune** (R-SD); and Representatives **Carolyn Maloney** (D-NY), **Hank Johnson** (D-GA) and **Gus Bilirakis** (R-FL).



Rep. Gus Bilirakis

"My family has been personally impacted by Parkinson's disease. The toll that this debilitating, rare disease has on patients and their families is tragic. However, the cutting-edge research taking place holds the promise for better treatments and a potential cure. Through the Parkinson's Caucus, we empower patients, give voice to those who are impacted and garner support for this vital research. I hope you will join this important cause."



Rep. Carolyn Maloney

"I am proud to serve as co-chair of the Parkinson's Disease Caucus, which advocates for strong funding for medical research and helps raise awareness about this disease. We have successfully secured hundreds of millions of dollars for life-saving research through the Department of Defense Parkinson's Research Program. With about 1 million Americans living with Parkinson's, the caucus is firmly committed to supporting patients, families and caregivers."

Please support
Americans
living with
Parkinson's
disease by
joining today!

CONTACT

Alex Graf

Office of Sen. Stabenow
alex_graf@stabenow.senate.gov

Shayne Woods

Office of Rep. Bilirakis
shayne.woods@mail.house.gov

About Parkinson's Disease

Parkinson's disease (PD) is a chronic neurodegenerative disease that gradually worsens over time. There is no treatment to slow, stop, or reverse the progression of the disease, nor is there a cure. Parkinson's affects approximately one million Americans and costs an estimated \$52 billion every year in medical and non-medical expenditures, nearly half of which is paid by the federal government. It is estimated that more than 1.6 million people in the United States will be impacted by Parkinson's disease by 2037, at an estimated economic burden of \$79 billion.

Existing Parkinson's treatments are limited in their ability to address symptoms and remain effective over time. There is no diagnostic test for Parkinson's, so the rate of under-diagnosis can be relatively high. Motor and non-motor symptoms can include (but are not limited to) resting tremor, stiffness and slowness of movement, as well as depression, sleep disorders, and cognitive impairment.

Please contact policy@michaeljfox.org or more information.